Proton pump inhibitors and vascular function: A prospective cross-over pilot study

Vascular Medicine (United Kingdom)

Volumn 20, Issue 4, 2015, Pages 309-316

  Ghebremariam, Yohannes T ^a   Cooke, John P ^a   Khan, Fouzia ^b   Thakker, Rahul N ^b   Chang, Peter ^b   Shah, Nigam H ^b   Nead, Kevin T ^b   Leeper, Nicholas J ^b,c  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

asymmetric dimethylarginine; cardiovascular risk factors; dimethylarginine dimethylaminohydrolase; nitric oxide; proton pump inhibitors

Indexed keywords

LANSOPRAZOLE; N(G),N(G) DIMETHYLARGININE; PLACEBO; PROTON PUMP INHIBITOR; ARGININE; BIOLOGICAL MARKER; N,N-DIMETHYLARGININE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANALYTICAL PARAMETERS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; FLOW MEDIATED VASODILATATION; HUMAN; MALE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REACTIVE HYPEREMIA INDEX; REPRODUCIBILITY; TEST RETEST RELIABILITY; TREATMENT DURATION; TREND STUDY; VASCULAR FUNCTION; VASODILATATION; ANALOGS AND DERIVATIVES; BLOOD; CALIFORNIA; CORONARY DISEASE; DRUG ADMINISTRATION; DRUG EFFECTS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RISK ASSESSMENT; TIME FACTOR; UPPER LIMB; VASCULARIZATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ARGININE; BIOMARKERS; CALIFORNIA; CORONARY DISEASE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LANSOPRAZOLE; MALE; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TIME FACTORS; UPPER EXTREMITY; VASODILATION; YOUNG ADULT;

EID: 84938766921     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X14568444     Document Type: Conference Paper

References (43)

1. Hershcovici T, Fass R,. Pharmacological management of GERD: where does it stand now? Trends Pharmacol Sci 2011; 32: 258-264.
2. Triadafilopoulos G,. Proton pump inhibitors for Barretts oesophagus. Gut 2000; 46: 144-146.
3. McColl KE,. Helicobacter pylori infection and long term proton pump inhibitor therapy. Gut 2004; 53: 5-7.
4. Peura DA, Berardi RR, Gonzalez J,. The value of branded proton pump inhibitors: formulary considerations. P T 2011; 36: 434-445.
5. US Food and Drug Administration (FDA). FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Postmarket Drug Safety Information for Patients and Providers, 2011. Available at: www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm213206.htm (. accessed 13 March 2015).
6. Stedman CA, Barclay ML,. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-978.
7. Simpson IJ, Marshall MR, Pilmore H,. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton) 2006; 11: 381-385.
8. Reimer C, Sondergaard B, Hilsted L,. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137: 80-87.
9. US Food and Drug Administration (FDA). FDA Drug Safety Podcast for Healthcare Professionals: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs)., 2009. Available at: www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm245455.htm (. accessed 13 March 2015).
10. US Food and Drug Administration (FDA). Proton Pump Inhibitors (PPI): Class Labeling Change., 2011. Available at: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213321.htm (. accessed 13 March 2015).
11. Ho PM, Maddox TM, Wang L,. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
12. Juurlink DN, Gomes T, Ko DT,. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-718.
13. Gilard M, Arnaud B, Cornily JC,. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
14. Charlot M, Grove EL, Hansen PR,. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342: d2690.
15. Li XQ, Andersson TB, Ahlstrom M,. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-827.
16. Goodman SG, Clare R, Pieper KS, Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 2012; 125: 978-986.
17. Charlot M, Ahlehoff O, Norgaard ML,. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010; 153: 378-386.
18. Cooke JP,. Asymmetrical dimethylarginine: the Uber marker? Circulation 2004; 109: 1813-1818.
19. Mittermayer F, Krzyzanowska K, Exner M,. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006; 26: 2536-2540.
20. Wilson AM, Shin DS, Weatherby C,. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med 2010; 15: 267-274.
21. Lu TM, Chung MY, Lin MW,. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 2011; 153: 135-140.
22. Ari H, Ari S, Erdogan E,. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine. Heart Vessels 2010; 25: 19-26.
23. Boger RH, Sullivan LM, Schwedhelm E,. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119: 1592-1600.
24. Wanby P, Teerlink T, Brudin L,. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 2006; 185: 271-277.
25. Ghebremariam YT, LePendu P, Lee JC,. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2013; 128: 845-853.
26. Versari D, Daghini E, Virdis A,. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32 Suppl 2: S314-321.
27. Hanson M, Gluckman P,. Endothelial dysfunction and cardiovascular disease: the role of predictive adaptive responses. Heart 2005; 91: 864-866.
28. Martin BJ, Anderson TJ,. Risk prediction in cardiovascular disease: the prognostic significance of endothelial dysfunction. Can J Cardiol 2009; 25 Suppl A: 15A-20A.
29. Ghebremariam YT, Lee JC, LePendu P,. Response to letters regarding article, €Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2014; 129: e428.
30. Schulze F, Wesemann R, Schwedhelm E,. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004; 42: 1377-1383.
31. Kwok CS, Jeevanantham V, Dawn B,. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol 2013; 167: 965-974.
32. Vallance P, Leone A, Calver A,. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
33. Boger RH, Bode-Boger SM, Szuba A,. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847.
34. Miyazaki H, Matsuoka H, Cooke JP,. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146.
35. Schnabel R, Blankenberg S, Lubos E,. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97: e53-59.
36. Wang J, Sim AS, Wang XL,. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006; 184: 383-388.
37. Shah NH, LePendu P, Bauer-Mehren A,. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLOS ONE 2015; 10: e0124653.
38. Cederberg C, Thomson AB, Mahachai V,. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 1992; 103: 913-918.
39. Hoepfl B, Rodenwaldt B, Pohl U,. EDHF, but not NO or prostaglandins, is critical to evoke a conducted dilation upon ACh in hamster arterioles. Am J Physiol Heart Circ Physiol 2002; 283: H996-H1004.
40. Cooke JP, Ghebremariam YT,. Dietary nitrate, nitric oxide, and restenosis. J Clin Invest 2011; 121: 1258-1260.
41. Kenjale AA, Ham KL, Stabler T,. Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease. J Appl Physiol 2011; 110: 1582-1591.
42. Truschel E, Jarczok MN, Fischer JE,. High-throughput ambulatory assessment of digital reactive hyperemia: concurrent validity with known cardiovascular risk factors and potential confounding. Prev Med 2009; 49: 468-472.
43. Moerland M, Kales AJ, Schrier L,. Evaluation of the EndoPAT as a tool to assess endothelial function. Int J Vasc Med 2012; 2012: 904141.